ANDA 76223, held by Sandoz. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 76223 (Metformin Hydrochloride), held by Sandoz, was first approved by FDA on Dec 14, 2004, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 14, 2004 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Metformin Hydrochloride500MG · tablet, extended release;oral | Metformin Hydrochloride | Discontinued |
| Aug 11, 2026 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 10, 2026 | Supplement 4Labeling · Standard review | Approved | None posted |
| Dec 14, 2004 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters